Watch for interim data from the upcoming Phase 2 trial in 2026–2027; the combination's safety and efficacy in AR-mutant mCRPC could validate Monte Rosa’s molecular glue platform and drive partnership or licensing interest. However, lack of near-term monetization and high development risk remain concerns.
Price Chart
Executive Summary
Monte Rosa Therapeutics announced a supply agreement with Johnson & Johnson to evaluate its investigational drug MRT-2359 in combination with ERLEADA® (apalutamide) in a planned Phase 2 study for metastatic castration-resistant prostate cancer (mCRPC) patients with AR mutations, expected to initiate in Q3 2026. The decision follows encouraging early clinical activity observed in a Phase 1/2 trial combining MRT-2359 with enzalutamide in heavily pretreated patients.
Key Facts
- Monte Rosa will sponsor and conduct a Phase 2 study of MRT-2359 in combination with Johnson & Johnson's ERLEADA® in AR-mutant mCRPC patients, expected to start in Q3 2026.
- The study will enroll up to 25 patients and assess PSA response, RECIST response, duration of response, PFS, rPFS, and safety.
- Positive early data from an ongoing Phase 1/2 study of MRT-2359 + enzalutamide were presented at ASCO GU 2026.
- Johnson & Johnson will supply ERLEADA®; no financial terms of the agreement were disclosed.
- MRT-2359 is a GSPT1-directed molecular glue degrader targeting MYC-driven cancers, including prostate cancer.
Financial Impact
No direct financial impact disclosed; potential long-term value if clinical activity is confirmed and program advances to registrational trials.
Risk Factors
- Clinical development risk: MRT-2359 remains early-stage; failure in Phase 2 would significantly devalue the program.
- Combination safety risk: ERLEADA® has known risks including fractures, falls, seizures, and severe skin reactions, which could complicate tolerability.
- Dilution risk: Monte Rosa may require future capital raises to fund development, potentially diluting shareholders.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256118 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | 8-K | $11.26 | awaiting T+60 | — | $10.59 (−5.99%) |
Sep 30, 2026 26d ago | Press Release | $11.26 | awaiting T+60 | — | $10.59 (−5.99%) |
Aug 6, 2026 11w ago | 8-K | $15.71 | awaiting T+60 | — | $10.59 (−32.62%) |
Jul 17, 2026 14w ago | Insider Cluster | $23.48 $9.89 | ▼ −57.88% | ▼ −62.72% | $10.59 (−54.92%) |
Jul 7, 2026 15w ago | Insider Cluster | $24.06 $11.93 | ▼ −50.42% | ▼ −52.73% | $10.59 (−56.01%) |
Jul 1, 2026 16w ago | Insider Cluster | $24.21 $11.72 | ▼ −51.59% | ▼ −54.60% | $10.59 (−56.28%) |
Jul 1, 2026 16w ago | Insider Cluster | $24.21 $11.72 | ▼ −51.59% | ▼ −54.60% | $10.59 (−56.28%) |
Jun 29, 2026 17w ago | 144 | $24.20 $11.89 | ▼ −50.87% | ▼ −54.43% | $10.59 (−56.26%) |
Jun 25, 2026 17w ago | Insider Cluster | $22.29 $12.60 | ▼ −43.47% | ▼ −49.56% | $10.59 (−52.51%) |
Jun 2, 2026 20w ago | Insider Cluster | $17.59 $14.32 | ▼ −18.59% | ▼ −21.09% | $10.59 (−39.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers